论文部分内容阅读
醒脑饮按相当于推荐临床剂量（ＡＣＤ）５、１０、２０倍，分别给大鼠灌胃（ｉｇ），阳性药对照组ｉｇ相当于１０倍ＡＣＤ的脑血康，连续给药７天，第７天给药后２ｈ，测优球蛋白溶解时间（ＥＬＴ），纤维蛋白降解产物（ＦＤＰ），动静脉旁路血栓。还一次性给药测Ｃｈａｎｄｌｅｒ氏体外血栓、体外血浆凝块溶解时间。结果体外血浆凝块溶解时间，ＦＤＰ在给药组之间，给药组与对照之间无明显差异；与对照组相比，中、大剂量组及阳性药对照组的Ｃｈａｎｄｌｅｒ氏体外血栓的长度、干重、湿重，动静脉旁路血栓于、湿重及ＥＬＴ统计上有显著性差异。且大剂量组的作用优于小剂量组。结果表明，醒脑饮能增加纤溶系统的活性，其体外试验和体内给药都有溶血栓作用，且大、中、小剂量组显现出明显的量效关系。
Xingnaoyin was given 5, 10, and 20 times the recommended clinical dose (ACD), and each rat was given intragastric administration (ig). The positive drug control group ig was equivalent to 10 times ACD brain blood for continuous administration for 7 days. On the 7th day after administration, 2 hours after administration, euglobulin lysis time (ELT), fibrin degradation product (FDP), and arteriovenous bypass thrombus were measured. The Chandler’s extracorporeal thrombus and in vitro plasma clot lysis times were also measured in a single dose. Results In vitro clot lysis time, there was no significant difference in FDP between the drug administration group and the control group; compared with the control group, the length of Chandler’s extracorporeal thrombus in the medium and high dose group and the positive drug control group. Dry weight, wet weight, arteriovenous bypass thrombosis, wet weight, and ELT statistics were significantly different. And the effect of large dose group was better than that of small dose group. The results showed that Xingnaoyin can increase the activity of fibrinolytic system. Both in vitro and in vivo administration have thrombolytic effect, and large dose, medium dose, and low dose groups show a clear dose-effect relationship.